Given LCRF‐0006 enhanced the cumulative delivery of D‐luciferin to MM tumors, and that ADH‐1 increased melanoma tumor delivery of, and response to, the plasma protein‐binding chemotherapeutic agent melphalan,21, 68 we hypothesized that LCRF‐0006 may similarly enhance MM tumor delivery of, and response to, bortezomib in vivo. Here, ADH1A is linked to neoplasm.